Clinical Trials Logo

HIV Infections clinical trials

View clinical trials related to HIV Infections.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03558438 Recruiting - HIV Infections Clinical Trials

Spanish Cohort of Patients With HIV Infection Older Than 50 Years for the Study of Fragility and Physical Function

FUNCFRAIL
Start date: May 7, 2018
Phase:
Study type: Observational

It's a prospective observational study to assess frailty and physical function

NCT ID: NCT03554408 Recruiting - Clinical trials for Human Immunodeficiency Virus

First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS

Start date: June 2018
Phase: Phase 1
Study type: Interventional

This first clinical study of 10-1074-LS will evaluate its safety, tolerability and pharmacokinetics profile when administered alone or in combination with 3BNC117-LS to HIV (human immunodeficiency virus) -infected and HIV-uninfected individuals.

NCT ID: NCT03526848 Recruiting - Clinical trials for Human Immunodeficiency Virus

3BNC117 and 10-1074 in ART-treated Individuals

Start date: June 5, 2018
Phase: Phase 1
Study type: Interventional

The proposed study is a phase 1, open label, randomized study to evaluate the safety and antiretroviral activity of seven infusions of 3BNC117 and 10-1074, administered intravenously at 30 mg/kg dose level, in human immunodeficiency virus (HIV)-infected individuals on combination antiretroviral therapy (ART) and during an analytical interruption of ART.

NCT ID: NCT03519373 Recruiting - Pregnancy Clinical Trials

Pertussis Immunization During Pregnancy & HIV Infection

Start date: March 1, 2017
Phase:
Study type: Observational

The impact of chronic HIV infection and pregnancy on different aspects of the humoral response to pertussis immunization with the TDaP vaccine will be studied. The parameters will be measured in 3 groups (HIV-infected pregnant, HIV-uninfected pregnant and HIV-uninfected non pregnant) at different time points before and after immunization (7-10 days, 30 days and at delivery). The transfer ratio and the quality of maternal antibodies will be studied in cord blood.

NCT ID: NCT03517631 Recruiting - HIV Infections Clinical Trials

An Efficacy and Safety Study of shRNA-modified CD34+ Cells in HIV-infected Patients.

Start date: February 27, 2018
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of autologous CD34+ cells that stably express multiplexed shRNA to treat HIV infection.

NCT ID: NCT03515772 Recruiting - HIV Infections Clinical Trials

Drug-drug Interactions Between Antiretroviral Drugs and Cardiovascular Drugs in Elderly Patients

Start date: April 23, 2018
Phase:
Study type: Observational

Ageing is characterized by physiological changes, which can impact drug pharmacokinetics and thereby cause drug-drug interactions. This study aims to assess the pharmacokinetics of amlodipine, atorvastatin and rosuvastatin in the presence of darunavir/ritonavir (inhibitor of drug metabolizing enzymes and drug transporters), by comparison with dolutegravir (no inhibitory effects on cytochromes or transporters involved in the disposition of the evaluated co-medications), in order to characterize the importance of drug-drug interactions in elderly individuals.

NCT ID: NCT03512964 Recruiting - Clinical trials for Human Immunodeficiency Virus

Rapid HIV Treatment Initiation, Access and Engagement in Care

Start date: November 29, 2016
Phase: Phase 2
Study type: Interventional

The investigators propose to evaluate Rapid HIV Treatment Initiation in Baltimore in newly and previously diagnosed HIV-positive patients not in care through identification of barriers, facilitators and acceptability of Rapid HIV Treatment Initiation among newly and previously diagnosed HIV-positive patients not in care identified at the Johns Hopkins East Baltimore campus and at the Baltimore City Health Department sexually transmitted disease clinics. Using this data, a protocol for Rapid HIV Treatment Initiation among newly and previously diagnosed HIV-positive patients not in care identified at the Johns Hopkins East Baltimore campus and the Baltimore City Health Department sexually transmitted disease clinics will be developed and pilot tested. This pilot data will be used to design a multi-site study evaluating the effectiveness of Rapid HIV Treatment Initiation versus facilitated linkage to care. A model for Rapid HIV Treatment Initiation in Baltimore could be generalized to cities where the HIV epidemic has a similar demographic and risk profile such as Washington DC, Atlanta, and New York City.

NCT ID: NCT03508908 Recruiting - HIV Infections Clinical Trials

Tambua Mapema Plus - to Discover HIV Infection Early and Prevent Onward Transmission

Start date: December 1, 2017
Phase: N/A
Study type: Interventional

This study will assess the impact of an HIV-1 RNA testing intervention targeting adult patients aged 18-39 years who seek urgent care for symptoms at primary care facilities and meet specific risk criteria for acute HIV infection. All newly diagnosed HIV-infected patients in the intervention arm will be linked to care and offered both immediate treatment and assisted partner notification. Partners will also be tested using the HIV testing intervention, and pre-exposure prophylaxis will be offered to uninfected individuals with HIV-infected partners. The cost-effectiveness of this intervention will be evaluated.

NCT ID: NCT03502005 Recruiting - Clinical trials for Human Immunodeficiency Virus

Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1

Start date: March 1, 2018
Phase: Phase 4
Study type: Interventional

This study evaluates the efficacy, safety and tolerability of switching from the older, established single tablet regimen of ATRIPLA® (EFV/FTC/TDF) to a new single tablet regimen of BIKTARVY® (BIC/FTC/TAF), in HIV-1 infected adult subjects who are virologically suppressed (HIV-1 RNA<50 copies/mL).

NCT ID: NCT03500302 Recruiting - Clinical trials for Coronary Artery Disease

Effect of Evolocumab on Coronary Endothelial Function

EVOLVE
Start date: November 22, 2017
Phase: Phase 2
Study type: Interventional

The investigators propose a pilot study using (1) MRI to assess coronary artery endothelial function, (2) brachial ultrasound to assess systemic endothelial function, (3) serum markers of inflammation and of endothelial cell function and (4) echocardiographic measures of left ventricular diastolic and systolic properties, before and following initiation of PCSK9 antibody in HIV positive subjects.